Uric acid: a translational journey in cerebroprotection that spanned preclinical and human data
EC Leira, AM Planas, AK Chauhan, A Chamorro - Neurology, 2023 - AAN Enterprises
Uric acid (UA) is a strong endogenous antioxidant that neutralizes the toxicity of peroxynitrite
and other reactive species on the neurovascular unit generated during and after acute brain …
and other reactive species on the neurovascular unit generated during and after acute brain …
[HTML][HTML] Immunothrombosis in neurovascular disease
ABSTRACT A State of the Art lecture titled" Immunothrombosis in Neurovascular Diseases"
was presented at the ISTH congress in 2023. Despite significant clinical advancements in …
was presented at the ISTH congress in 2023. Despite significant clinical advancements in …
The role of oxidative stress in blood–brain barrier disruption during ischemic stroke: Antioxidants in clinical trials
JJ Lochhead, PT Ronaldson, TP Davis - Biochemical Pharmacology, 2024 - Elsevier
Ischemic stroke is one of the leading causes of death and disability. Occlusion and
reperfusion of cerebral blood vessels (ie, ischemia/reperfusion (I/R) injury) generates …
reperfusion of cerebral blood vessels (ie, ischemia/reperfusion (I/R) injury) generates …
Building reproducible bridges to cross the “valley of death”
TM Errington - The Journal of Clinical Investigation, 2024 - Am Soc Clin Investig
Center for Open Science, Charlottesville, Virginia, USA. Research is cumulative. New
investigations build on, challenge, or qualify claims based on prior evidence. When we have …
investigations build on, challenge, or qualify claims based on prior evidence. When we have …
Biological and Procedural Predictors of Outcome in the Stroke Preclinical Assessment Network (SPAN) Trial
A Morais, T Imai, X Jin, JJ Locascio… - Circulation …, 2023 - ahajournals.org
BACKGROUND: The SPAN trial (Stroke Preclinical Assessment Network) is the largest
preclinical study testing acute stroke interventions in experimental focal cerebral ischemia …
preclinical study testing acute stroke interventions in experimental focal cerebral ischemia …
Evolution and Future of Stroke Trials
JP Broderick, EA Mistry - Stroke, 2024 - ahajournals.org
The basic question that clinical trials try to answer for patients and health care providers is
whether a therapy has a positive biologic effect that either prevents disease or improves the …
whether a therapy has a positive biologic effect that either prevents disease or improves the …
[HTML][HTML] New Perspectives in Neuroprotection for Ischemic Stroke
M Pérez-Mato, E López-Arias, A Bugallo-Casal… - Neuroscience, 2024 - Elsevier
The constant failure of new neuroprotective therapies for ischemic stroke has partially halted
the search for new therapies in recent years, mainly because of the high investment risk …
the search for new therapies in recent years, mainly because of the high investment risk …
Angiotensin II Type 2 Receptor Agonism Alleviates Progressive Post-stroke Cognitive Impairment in Aged Spontaneously Hypertensive Rats
A Alshammari, B Pillai, P Kamat, TW Jones… - Translational Stroke …, 2024 - Springer
Hypertension and aging are leading risk factors for stroke and vascular contributions to
cognitive impairment and dementia (VCID). Most animal models fail to capture the complex …
cognitive impairment and dementia (VCID). Most animal models fail to capture the complex …
Mesenchymal stromal cells in acute respiratory distress syndrome: more questions than answers
JE Millar, CM O'Kane - American Journal of Respiratory and Critical …, 2023 - atsjournals.org
An effective treatment for acute respiratory distress syndrome (ARDS) remains elusive.
Preclinical studies have demonstrated therapeutic potential of multiple mesenchymal …
Preclinical studies have demonstrated therapeutic potential of multiple mesenchymal …
Priming and Combined Strategies for the Application of Mesenchymal Stem Cells in Ischemic Stroke: A Promising Approach
H Tian, F Tian, D Ma, B Xiao, Z Ding, X Zhai… - Molecular …, 2024 - Springer
Ischemic stroke (IS) is a leading cause of death and disability worldwide. Tissue
plasminogen activator (tPA) administration and mechanical thrombectomy are the main …
plasminogen activator (tPA) administration and mechanical thrombectomy are the main …